Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Retatrutide is an investigational agent that produces very large body-weight reductions in early trials by simultaneously engaging GLP-1R, GIPR, and GCGR to enhance satiety, energy expenditure, and glycemic control2575, Thymosin Alpha-1 is clinically used in some countries as an immunomodulator for chronic hepatitis B/C and as an adjuvant in cancer therapy, enhancing cell-mediated immunity41487.
While Retatrutide works as a triple incretin agonist peptide derived from a GIP backbone and engineered to activate GLP-1, GIP, and glucagon receptors, with non-natural residues and fatty-acid conjugation that confer long half-life and balanced multi-receptor signaling256575, Thymosin Alpha-1 is a 28-amino-acid thymic peptide fragment of prothymosin alpha that activates dendritic cells and T cells primarily via TLR9/MyD88/NF-κB signaling, enhancing Th1 responses and NK-cell cytotoxicity414.
Retatrutide
Not assigned in the current dataset.
Thymosin Alpha-1
PTMA
Retatrutide and Thymosin Alpha-1 are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Retatrutide is more often discussed in the realm of Metabolic and endocrine, whereas Thymosin Alpha-1 is more often associated with the realm of Immunology and inflammation and Oncology. They also influence different molecular systems, with Retatrutide tracking more closely to GLP-1 receptor while Thymosin Alpha-1 centers more on Toll-like receptor. Retatrutide has a more synthetic analog origin, while Thymosin Alpha-1 is closer to natural endogenous background and their development context also differs, with Retatrutide in Clinical phase 3 while Thymosin Alpha-1 is approved. Retatrutide takes the form of a peptide conjugate, whereas Thymosin Alpha-1 is closer to a linear peptide, Retatrutide carries lipidation features, while Thymosin Alpha-1 instead reflects acetylation changes; while their sequence patterns also diverge, with Retatrutide showing alpha-helical domain features and Thymosin Alpha-1 showing protein-mimetic sequence features.